特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
959714

Onvansertib + Abiraterone:新薬の考察と2030年までの市場予測

Onvansertib + Abiraterone - Emerging Drug Insight and Market Forecast - 2030

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 50 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
Onvansertib + Abiraterone:新薬の考察と2030年までの市場予測
出版日: 2020年09月08日
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

第3世代のアデノシン三リン酸阻害剤であるOnvansertibは、化学療法や標的薬剤と組み合わせることで効果を発揮すると期待されています。Onvansertib (PCM-075) と酢酸アビラテロン(Zytiga)を併用した第II相の臨床試験では、ほとんどの被験者で前立腺特異抗原(PSA)のレベルが低下しています。

当レポートは、米国、ドイツ、フランス、イタリア、スペイン、英国、日本の主要7ヶ国におけるOnvansertib + Abirateroneの市場を調査し、2030年までの展望を示したもので、医薬品の概要、市場の評価、SWOT分析、競合企業各社のプロファイル、他の新たな治療薬などの情報を提供しています。

調査範囲

  • 製品の説明、作用機序、投与量と投与方法、 研究開発活動を含む包括的な製品概要
  • 規制機関の承認手続きのマイルストーンなど開発活動の詳細
  • 米国 、欧州、日本における医薬品研究開発の詳細
  • ONVANSERTIB + ABIRATERONEに関する有効期限を含めた特許情報
  • 2030年までのONVANSERTIB + ABIRATERONEの売上高予測
  • 開発後期段階(第III相)にある新たな治療薬の総合的な情報
  • アナリストの考察とSWOT分析

レポートのハイライト

  • 今後前立腺がん治療薬の市場シナリオは、世界各国で進められている研究開発と医療費の増加に伴って大きく変わり、市場規模の拡大により参入する製薬会社が増える見通しです。
  • 企業と研究者は、ONVANSERTIB + ABIRATERONEの優位性を高める機会を模索しています。現在開発中の治療法では、病状を治療/改善するための新たなアプローチが焦点となっています。
  • ONVANSERTIB + ABIRATERONEと競合する新たな競合製品が登場しており、近い将来市場に大きな影響を与えると思われます。

当レポートが対応している主な疑問点

  • ONVANSERTIB + ABIRATERONEを開発しているのはどの企業か。
  • ONVANSERTIB + ABIRATERONEの開発に利用されている技術は何か。
  • ONVANSERTIB + ABIRATERONEの製品タイプ、投与経路、作用機序はどのようなものか。
  • 臨床試験の状況と完了日はいつか。
  • ONVANSERTIB + ABIRATERONEの開発に関連する主な協力、合併、買収、ライセンシングなどの動きはどうなっているのか。
  • ONVANSERTIB + ABIRATERONEに付与された主な指定は何か。
  • ONVANSERTIB + ABIRATERONEの予測される市場シナリオはどのようなものか。
  • ONVANSERTIB + ABIRATERONEのこれまでの経緯と今後の見通しはどのようなものか。
  • 米国、ドイツ、フランス、イタリア、スペイン、英国、日本でのONVANSERTIB + ABIRATERONEの売上予測はどうか。
  • 利用可能な他の新製品は何か。またこれらの製品とはどのような形で競合するのか。
  • 現在開発後期段階にある新たな治療薬は何か。

目次

第1章 医薬品の概要

  • 製品の詳細
  • 作用機序
  • 投薬と管理
  • 研究開発活動
    • 臨床開発
    • 安全性と有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国の市場分析
  • 米国市場
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場
  • 日本市場

第3章 SWOT分析

第4章 アナリストの見解

第5章 市場での競合

第6章 他の新たな治療薬

第7章 付録

第8章 レポート購入オプション

図表

List of Tables

  • Table 1 ONVANSERTIB + ABIRATERONE, Description
  • Table 2 ONVANSERTIB + ABIRATERONE, Clinical Trial Description
  • Table 3 ONVANSERTIB + ABIRATERONE, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of ONVANSERTIB + ABIRATERONE
  • Figure 2 Patent Details, ONVANSERTIB + ABIRATERONE
  • Figure 3 ONVANSERTIB + ABIRATERONE, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 ONVANSERTIB + ABIRATERONE, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 ONVANSERTIB + ABIRATERONE, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 ONVANSERTIB + ABIRATERONE, Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0065

"Onvansertib + Abiraterone- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prostate cancer in 7 Major Markets. A detailed picture of the ONVANSERTIB + ABIRATERONE in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

Onvansertib, a third-generation first-in-class, adenosine triphosphate inhibitor is showing promise when combined with chemotherapies and targeted agents. The combination of onvansertib (PCM-075) with abiraterone acetate (Zytiga) decreased the prostate-specific antigen (PSA) levels in most of the evaluable patients treated in a phase II study (NCT03414034), which used the combination in adult patients with metastatic castration-resistance prostate cancer (mCRPC), according to a press release from onvansertib developer, Trovagene, Inc. The results presented at the European Multidisciplinary Congress on Urological Cancers (EMUC) show that after 3 months of treatment with onvansertib plus abiraterone acetate, 60% of patients has a partial response (PR) or stable disease.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around ONVANSERTIB + ABIRATERONE.
  • The report contains forecasted sales for ONVANSERTIB + ABIRATERONE till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Prostate cancer.
  • The report also features the SWOT analysis with analyst insights and key findings of ONVANSERTIB + ABIRATERONE.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ONVANSERTIB + ABIRATERONE Analytical Perspective by DelveInsight

  • In-depth ONVANSERTIB + ABIRATERONE Market Assessment

This report provides a detailed market assessment of ONVANSERTIB + ABIRATERONE in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • ONVANSERTIB + ABIRATERONE Clinical Assessment

The report provides the clinical trials information of ONVANSERTIB + ABIRATERONE covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Prostate cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence ONVANSERTIB + ABIRATERONE dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Prostate cancer are giving market competition to ONVANSERTIB + ABIRATERONE and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of ONVANSERTIB + ABIRATERONE.
  • Our in-depth analysis of the forecasted sales data of ONVANSERTIB + ABIRATERONE from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ONVANSERTIB + ABIRATERONE.

Key Questions:

  • Which company is developing ONVANSERTIB + ABIRATERONE along with the phase of the clinical study?
  • What is the technology utilized in the development of ONVANSERTIB + ABIRATERONE?
  • What is the product type, route of administration and mechanism of action of ONVANSERTIB + ABIRATERONE?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ONVANSERTIB + ABIRATERONE development?
  • What are the key designations that have been granted to ONVANSERTIB + ABIRATERONE?
  • What is the forecasted market scenario of ONVANSERTIB + ABIRATERONE?
  • What is the history of ONVANSERTIB + ABIRATERONE and what is its future?
  • What is the forecasted sales of ONVANSERTIB + ABIRATERONE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to ONVANSERTIB + ABIRATERONE?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.